Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Acconeer - Making 2026 Sense-ational

Acconeer

Acconeer's first quarter 2025 net sales growth of 20% y/y (or -12% adjusted for the postponed order) was weaker than anticipated. This, coupled with slightly higher OPEX, resulted in an EBITDA miss. However, results remain volatile as they are contingent on specific order shipments. Despite the miss, the share price held firm, owing to the strong cash position secured via the rights issue announced with the fourth-quarter report. The reorganisation has bolstered customer confidence, leading to market share gains and larger orders from an increased number of customers. Redeye believes the key catalysts will be larger orders within the product areas and an A2 design win, which would support investor confidence in the reiterated >SEK300m 2027 target. Redeye revised its estimates and fair value range accordingly.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Acconeer - Making 2026 Sense-ational

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.